Home › Research › Digital health tools
Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: A machine learning approach
Bachli MB, Sedeño L, Ochab JK, Piguet O, Kumfor F, Reyes P, Torralva T, Roca M et al.. NeuroImage, 2019-12-10
Topic: Risk, prevention and care in population studies
Plain-language summary
Accurate early diagnosis of neurodegenerative diseases represents a growing challenge for current clinical practice. Promisingly, current tools can be complemented by computational decision-support methods to objectively analyze multidimensional measures and increase diagnostic confidence. Yet, widespread application of these tools cannot be recommended unless they are proven to perform consistently and reproducibly across samples from different countries. We implemented machine-learning algorithms to evaluate the prediction power of neurocognitive biomarkers (behavioral and imaging measures) for classifying two neurodegenerative conditions -Alzheimer Disease (AD) and behavioral variant frontotemporal dementia (bvFTD)- across three different countries (>200 participants). We use machine-learning tools integrating multimodal measures such as cognitive scores (executive functions and cognitive screening) and brain atrophy volume (voxel based morphometry from fronto-temporo-insular regions in bvFTD, and temporo-parietal regions in AD) to identify the most relevant features in predicting the incidence of the diseases. In the Country-1 cohort, predictions of AD and bvFTD became maximally improved upon inclusion of cognitive screenings outcomes combined with atrophy levels. Multimodal training data from this cohort allowed predicting both AD and bvFTD in the other two novel datasets from other countries with high accuracy (>90%), demonstrating the robustness of the approach as well as the differential specificity and reliability of behavioral and neural markers for each condition. In sum, this is the first study, across centers and countries, to validate the predictive power of cognitive signatures combined with atrophy levels for contrastive neurodegenerative conditions, validating a benchmark for future assessments of reliability and reproducibility.
What this study adds
Evidence grade: Moderate
The record lists 200 participants. Machine learning using cognitive scores and brain atrophy measures classified Alzheimer's disease and behavioral variant frontotemporal dementia across three countries, with the best predictions when cognitive screening and atrophy levels were combined. This supports using these tools to help diagnose these conditions, but it does not show any treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bachli, M. B., Sedeño, L., Ochab, J. K., Piguet, O., Kumfor, F., Reyes, P., et al. (2020). Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: A machine learning approach. NeuroImage. https://doi.org/10.1016/j.neuroimage.2019.116456
Vancouver
Bachli MB, Sedeño L, Ochab JK, Piguet O, Kumfor F, Reyes P, et al. Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: A machine learning approach. NeuroImage. 2020. doi:10.1016/j.neuroimage.2019.116456. PMID: 31841681.
BibTeX
@article{bachli2020-31841681,
author = {Bachli, M. B. and Sedeño, L. and Ochab, J. K. and Piguet, O. and Kumfor, F. and Reyes, P. and Torralva, T. and Roca, M. and others},
title = {{Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: A machine learning approach}},
journal = {NeuroImage},
year = {2020},
doi = {10.1016/j.neuroimage.2019.116456},
pmid = {31841681},
url = {https://doi.org/10.1016/j.neuroimage.2019.116456}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We implemented machine-learning algorithms to evaluate the prediction power of neurocognitive biomarkers (behavioral and imaging measures) for classifying two neurodegenerative conditions -Alzheimer Disease (AD) and behavioral variant frontotemporal dementia (bvFTD)- across three different countries (>200 participants).
- We use machine-learning tools integrating multimodal measures such as cognitive scores (executive functions and cognitive screening) and brain atrophy volume (voxel based morphometry from fronto-temporo-insular regions in bvFTD, and temporo-parietal regions in AD) to identify the most relevant features in predicting the incidence of the diseases.
- In the Country-1 cohort, predictions of AD and bvFTD became maximally improved upon inclusion of cognitive screenings outcomes combined with atrophy levels.
- Multimodal training data from this cohort allowed predicting both AD and bvFTD in the other two novel datasets from other countries with high accuracy (>90%), demonstrating the robustness of the approach as well as the differential specificity and reliability of behavioral and neural markers for each condition.
- In sum, this is the first study, across centers and countries, to validate the predictive power of cognitive signatures combined with atrophy levels for contrastive neurodegenerative conditions, validating a benchmark for future assessments of reliability and reproducibility.
Why it matters
Machine learning using cognitive scores and brain atrophy measures classified Alzheimer's disease and behavioral variant frontotemporal dementia across three countries, with the best predictions when cognitive screening and atrophy levels were combined. This supports using these tools to help diagnose these conditions, but it does not show any treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Participants200
- Evidence strengthModerate
How this study scored 55/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (NeuroImage) |
| Journal's citation record | 4 / 4 | NeuroImage: journal h-index 523 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 200 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 57 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.1 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 3 / 6 | Cited 5.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 2 / 4 | Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Dante R. Chialvo: h-index 54 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Sydney: institution h-index 1,466 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 18 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31841681) |
| Free to read | 2 / 2 | Free to read |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.neuroimage.2019.116456
- PubMed: 31841681
- Original source →
- Free full text: NeuroImage →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Digital health tools from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.